ArticleJournal of virology2002
Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer.Journal of hematology & oncology · 2025Review
- mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.Frontiers in immunology · 2023Review
- Current view on novel vaccine technologies to combat human infectious diseases.Applied microbiology and biotechnology · 2022Review
- The Limitless Future of RNA Therapeutics.Frontiers in bioengineering and biotechnology · 2021Review
- Advances in mRNA Vaccines for Infectious Diseases.Frontiers in immunology · 2019Review
- Mosquito cell-derived West Nile virus replicon particles mimic arbovirus inoculum and have reduced spread in mice.PLoS neglected tropical diseases · 2017Article
- Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.Journal of virology · 2015Article
- mRNA-based therapeutics--developing a new class of drugs.Nature reviews. Drug discovery · 2014Review
- A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.Therapeutic advances in vaccines · 2014Review
- RNA replicon delivery via lipid-complexed PRINT protein particles.Molecular pharmaceutics · 2013Article
- Are trans-complementation systems suitable for hepatitis C virus life cycle studies?Journal of viral hepatitis · 2013Review
- Immunogenicity of a DNA-launched replicon-based canine parvovirus DNA vaccine expressing VP2 antigen in dogs.Research in veterinary science · 2012Article
- Article
- A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy.Gene therapy · 2009Article
- Article
- Long-term storage of DNA-free RNA for use in vaccine studies.BioTechniques · 2007Article
- Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.Clinical and vaccine immunology : CVI · 2007Article
- Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.Journal of virology · 2006Review
- Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors.Cancer immunology, immunotherapy : CII · 2006Article
- Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.Journal of virology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability of self-replicating RNA (replicon) vaccine vectors derived from the Australian flavivirus Kunjin (KUN) to induce protective alphabeta CD8+ T-cell responses was examined. KUN replicons encoding a model immunogen were delivered by three different vaccine modalities: (i) as naked RNA transcribed in vitro, (ii) as plasmid DNA constructed to allow in vivo transcription of replicon RNA by cellular RNA polymerase II (DNA based), and (iii) as replicon RNA encapsidated into virus-like particles. A single immunization with any of these KUN replicon vaccines induced CD8+ T-cell responses at levels comparable to those induced by recombinant vaccinia virus encoding the same immunogen. Immunization with only 0.1 microg of DNA-based KUN replicons elicited CD8+ T-cell responses similar to those seen after immunization with 100 microg of a conventional DNA vaccine. Naked RNA immunization with KUN replicons also protected mice against challenges with recombinant vaccinia virus and B16 tumor cells. These results demonstrate the value of KUN replicon vectors for inducing protective antiviral and anticancer CD8+ T-cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.